Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Visen Medical Inc. is active in the Biotechnology & Pharmaceuticals technology area and currently has 1 pending office action. This action is situated in 1 distinct art unit, which aligns with the company's focus on medical and pharmaceutical technology. The company's current prosecution is highly concentrated in this single matter. The presence of only 1 pending matter indicates a streamlined prosecution phase for the company's current patent filings.
The portfolio is under the review of 1 distinct examiner. JONES, DAMERON LEVEST is the busiest examiner, holding 1 busiest examiner pending action. This means that all current feedback from the patent office for Visen Medical Inc. is coming from this 1 individual. This concentration of 1 pending office action under 1 distinct examiner in the Biotechnology & Pharmaceuticals field allows for a very focused legal strategy.
Because JONES, DAMERON LEVEST is the sole examiner, his specific history and preferences will determine the success of the 1 busiest examiner pending action. This lack of examiner diversity reduces the complexity of managing the portfolio's current active matters. Practitioners can focus their resources on addressing the specific concerns of this 1 distinct examiner within the 1 distinct art unit. This targeted approach is essential for resolving the current 1 pending office action efficiently.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES, DAMERON LEVEST | 1 | 67.7% | +31.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18675875 | 4,4-DISUBSTITUTED CYCLOHEXYL BRIDGED HEPTAMETHINE CYANINE DYES AND USES THEREOF | JONES, DAMERON LEVEST | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18675875 | 4,4-DISUBSTITUTED CYCLOHEXYL BRIDGED HEPTAMETHINE CYANINE DYES AND USES THEREOF | JONES, DAMERON LEVEST | 1618 | DP | Non-Final OA | — | Pending | May 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial